BackCerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings Other Current Liabilities

Latest other current liabilities for CERE: $73M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$73.27M
39.25% YoYΔ $20.65M vs prior year quarter

Peer average / median

Loading

Cerevel Therapeutics Holdings Other Current Liabilities History

Loading

Cerevel Therapeutics Holdings vs. peers: Other Current Liabilities Comparison

Loading

Cerevel Therapeutics Holdings Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cerevel Therapeutics Holdings (CERE) FAQ

Cerevel Therapeutics Holdings (CERE) currently reports a other current liabilities of $73M as of March 2024. That compares with $53M in the prior-year period — up 39.3% year over year. Use the charts on this page to explore Cerevel Therapeutics Holdings's other current liabilities history and peer comparisons.

Cerevel Therapeutics Holdings's other current liabilities increased from $53M to $73M — a 39.3% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cerevel Therapeutics Holdings reported $73M in other current liabilities as of March 2024. That compares with $53M in the prior-year period — up 39.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $73M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cerevel Therapeutics Holdings, and consider following CERE for alerts when major investors trade the stock.

Cerevel Therapeutics Holdings is classified in the Healthcare sector. On other current liabilities, it currently shows $73M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CERE with unrelated industries.